Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Obrixtamig - Boehringer Ingelheim

Next Previous
Drug Profile

Obrixtamig - Boehringer Ingelheim

Alternative Names: BI-764532; DLL3/CD3 T-cell engager - Boehringer Ingelheim; OBT-620

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours; Small cell lung cancer
  • Phase I Glioma

Most Recent Events

  • 30 May 2025 Efficacy and adverse events data from a phase I DAREONTM-9 trial in Small cell lung cancer presented at the at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
  • 22 May 2025 Updated efficacy and adverse events data from a phase I trial in Small cell lung cancer and Neuroendocrine tumours released by Boehringer Ingelheim
  • 13 Sep 2024 Updated efficacy and adverse events data from a phase I trial in Small cell lung cancer and Neuroendocrine tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top